

## Catalog # 10-2983 SB-525334

CAS# 356559-20-1

6-[2-(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline Lot # X106813

Potent and selective inhibitor of the transforming growth factor beta 1 receptor, activin receptor-like kinase (ALK5),  $IC_{50} = 14.3$  nM and ALK4 ( $IC_{50} = 58.5$  nM) with no activity at ALK2, 3 and 6.¹ Blocks fibrosis markers and renal injury in the puromycin-induced nephritis model.¹ It causes significant attenuation in Smad2/3 nuclear translocation, decrease in CTGF-expressing cells, myofibroblast proliferation and type 1 collagen deposition resulting in an overall attenuation in bleomycin-induced pulmonary fibrosis.² Sensitizes drug-resistant pancreatic cancer cells to gemcitabine.³ Cell permeable and active *in vivo*.

- 1) Grygielko et al. (2005), Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factorbeta type I receptor kinase in puromycin-induced nephritis; J. Pharmacol. Exp. Ther. **313** 943
- 2) Higashiyama *et al.* (2007), *Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis*; Exp. Mol. Pathol. **83** 39
- 3) Kim et al. (2012), Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine; Anticancer Res. **32** 799

## PHYSICAL DATA

Purity: 99% by HPLC

NMR: (Conforms)

Solubility: DMSO (up to 30 mg/ml)

Physical Description: Yellow solid

Storage and Stability: Store as supplied desiccated at -20°C for up to 2 years from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.